Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received a consensus recommendation of “Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $23.00.

Several research firms have recently issued reports on STOK. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright increased their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares of the company’s stock, valued at $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the sale, the general counsel now directly owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 in the last 90 days. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in STOK. Bank of New York Mellon Corp grew its stake in Stoke Therapeutics by 1.4% in the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after acquiring an additional 1,330 shares during the period. Graham Capital Management L.P. lifted its holdings in shares of Stoke Therapeutics by 8.5% in the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after purchasing an additional 1,453 shares in the last quarter. Gilder Gagnon Howe & Co. LLC grew its position in Stoke Therapeutics by 2.0% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock valued at $1,021,000 after purchasing an additional 1,791 shares during the period. Price T Rowe Associates Inc. MD grew its position in Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after purchasing an additional 2,215 shares during the period. Finally, Rhumbline Advisers increased its stake in Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after purchasing an additional 2,787 shares in the last quarter.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $8.50 on Tuesday. The business has a 50 day moving average of $10.47 and a 200-day moving average of $12.22. The company has a market capitalization of $450.22 million, a P/E ratio of -4.05 and a beta of 0.95. Stoke Therapeutics has a 1 year low of $5.60 and a 1 year high of $17.58.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.